Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Treasury Shares (2022 - 2025)

Historic Treasury Shares for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $278347.0.

  • Atara Biotherapeutics' Treasury Shares fell 4620.27% to $278347.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $278347.0, marking a year-over-year decrease of 4620.27%. This contributed to the annual value of $414470.0 for FY2024, which is 6531.92% up from last year.
  • Atara Biotherapeutics' Treasury Shares amounted to $278347.0 in Q3 2025, which was down 4620.27% from $503640.0 recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Treasury Shares ranged from a high of $16.5 million in Q1 2024 and a low of $250709.0 during Q4 2023
  • Its 4-year average for Treasury Shares is $5.2 million, with a median of $6.7 million in 2022.
  • As far as peak fluctuations go, Atara Biotherapeutics' Treasury Shares tumbled by 9626.29% in 2023, and later soared by 6531.92% in 2024.
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Treasury Shares stood at $6.7 million in 2022, then crashed by 96.26% to $250709.0 in 2023, then soared by 65.32% to $414470.0 in 2024, then tumbled by 32.84% to $278347.0 in 2025.
  • Its last three reported values are $278347.0 in Q3 2025, $503640.0 for Q2 2025, and $677948.0 during Q1 2025.